<DOC>
	<DOCNO>NCT02499380</DOCNO>
	<brief_summary>The objective post-marketing study advance understand mechanism action CE mark RePneu Coil observe change lung physiology cardiac performance patient emphysema treat RePneu Coils , use intend .</brief_summary>
	<brief_title>Changes Lung Physiology Cardiac Performance Patients With Emphysema Post Bilateral RePneu Coil Treatment</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>1 . Adult subject diagnose emphysematous type COPD . 2 . CT scan indicate bilateral emphysema , sufficient lung parenchyma coil deployment ( base PneumRx CT score ) criterion . 3 . Subject postbronchodilator FEV1 ≤45 % predict . 4 . Subject Total Lung Capacity &gt; 100 % predict . 5 . Subject residual volume ( RV ) ≥175 % predict . 6 . Subject mark dyspnea score ≥2 mMRC scale 04 . 7 . Subject read , understood sign Informed Consent form . 8 . Subject receive Pneumococcal Influenza vaccination consistent local recommendation and/or policy . 1 . Subject comorbidities may significantly reduce subject 's ability improve exercise capacity ( e.g . severe arthritis , plan knee surgery ) baseline limitation due dyspnea . 2 . Subject change FEV1 &gt; 20 % ( , subject prebronchodilator FEV1 1 L , change &gt; 200 mL ) postbronchodilator unless investigator confirm mean subject asthma . 3 . Subject severe gas exchange abnormality define : PaCO2 &gt; 55 mm Hg PaO2 &lt; 45 mm Hg room air ( High altitude criterion : PaO2 &lt; 30 mm Hg ) 4 . Subject severe pulmonary hypertension define right ventricular systolic pressure &gt; 50 mm Hg via right heart catheterization and/or echocardiogram . 5 . Subject evidence severe disease ( , limit , lung cancer renal failure ) , judgment investigator may compromise survival subject duration study . 6 . Subject pregnant lactating , plan become pregnant within study timeframe . 7 . Subject inability tolerate bronchoscopy moderate sedation general anesthesia . 8 . Subject clinically significant bronchiectasis . 9 . Subject previous LVR surgery , lung transplantation , lobectomy BLVR treatment either lung . 10 . Subject participated study treat COPD use high dose radiation . 11 . Subject involved pulmonary drug device study within 30 day prior study . 12 . Subject chronically take &gt; 20 mg prednisone ( equivalent dose similar steroid ) daily . 13 . Subject require high level chronic immunomodulatory therapy treat moderate severe chronic inflammatory autoimmune disorder . 14 . Subject type antiplatelet anticoagulant therapy stop seven ( 7 ) day prior procedure . 15 . Subject sensitivity allergy Nickel . 16 . Subject know sensitivity drug require perform bronchoscopy . 17 . Subject diagnose alpha1 antitrypsin deficiency ( AATD ) . 18 . Subject disease , condition ( ) habit ( ) would interfere completion study followup assessment , would increase risk bronchoscopy assessment , judgment investigator would potentially interfere compliance study would adversely affect study outcome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>RePneu</keyword>
	<keyword>Coil</keyword>
	<keyword>LVRC</keyword>
	<keyword>PneumRx</keyword>
</DOC>